Search Results

relying on descriptive observations—“looks like a shift,” “seems like baseline activation”—you’re leaving risk

Automates New Radioligand Therapy Production Plant Novartis’ Lutathera reduces disease progression risk

transport by CCHCR1 via direct interaction Industry News Novartis Lutathera® significantly reduced risk

a G-protein coupled receptor-related gene signature through bioinformatics analysis to construct a risk

This scarcity made the field both exciting and high-risk.

Separate effect size from time:  Use allosteric modulators to expand therapeutic index and reduce overdose risk